Sunshine Biopharma Secures Canadian Approval for Generic Enalapril Tablets
Sunshine Biopharma Inc. (NASDAQ:SBFM) has received regulatory approval in Canada to market its generic version of the antihypertensive drug Enalapril, also known as Vasotec. The medication will be available in four dosage strengths and is expected to reach retail pharmacies by year-end 2026 through Nora Pharma Inc., a wholly owned Canadian subsidiary with an established distribution network. The approval marks another step for the company's expansion into first-line hypertension treatments within Canada, where it already markets 60 generic prescription drugs. The global antihypertensive drug market is projected to grow from $25.94 billion in 2025 to $37.24 billion by 2034 at a compound annual growth rate of 4.1%. Canada itself represents the sixth-largest pharmaceutical market globally. Sunshine Biopharma also recently secured approval for generic amoxicillin and completed a reverse stock split earlier this year to meet Nasdaq listing requirements.
Tickers: $SBFM
Topics: canada generic_drugs pharmaceuticals